Danish pharmaceutical firm Novo Nordisk has received biologics licence application (BLA) approval from the US Food and Drug Administration (FDA) for its recombinant coagulation factor VIII, Novoeight. Novoeight is intended for adults and ...
Tags: Novo Nordisk, Drug
Danish pharmaceutical company Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing approval for its NovoEight (turoctocog alfa), ...
Tags: Novo Nordisk, Novoeight
Novo Nordisk is seeking regulatory approval for a recombinant coagulation factor VIII, turoctocog alfa (NN7008), intended for prevention and treatment of bleeding in people with haemophilia A, in the Europe and the US. The filing for ...
Tags: Novo Nordisk, recombinant coagulation factor VIII, haemophilia